{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:31:57Z","timestamp":1784302317942,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01297-9","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:23:32Z","timestamp":1745223812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medication Induced Dyslipidemia in Children"],"prefix":"10.1007","volume":"27","author":[{"given":"Minali","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"1297_CR1","unstructured":"Pappan N, Awosika AO, Rehman A. Dyslipidemia. [internet]n: StatPearls [Internet]. StatPearls Publishing. 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560891\/"},{"issue":"1","key":"1297_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14423\/SMJ.0000000000000219","volume":"108","author":"DP Wilson","year":"2015","unstructured":"Wilson DP, McNeal C, Blackett P. Pediatric dyslipidemia: recommendations for clinical management. South Med J. 2015;108(1):7\u201314. https:\/\/doi.org\/10.14423\/SMJ.0000000000000219.","journal-title":"South Med J"},{"key":"1297_CR3","unstructured":"Herink M, Ito MK. Medication induced changes in lipid and lipoproteins. In: Feingold KR, Anawalt B, Blackman MR, et al. editors. Endotext [Internet]. MDText.com, Inc.; 2000. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326739\/."},{"issue":"Suppl 5","key":"1297_CR4","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","volume":"128","author":"Expert panel on integrated guidelines for cardiovascular","year":"2011","unstructured":"Expert panel on integrated guidelines for cardiovascular. Health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213\u201356. https:\/\/doi.org\/10.1542\/peds.2009-2107C.","journal-title":"Pediatrics"},{"issue":"14","key":"1297_CR5","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.3390\/ijms22147622","volume":"22","author":"C MacLeod","year":"2021","unstructured":"MacLeod C, Hadoke PWF, Nixon M. Glucocorticoids: fueling the fire of atherosclerosis or therapeutic extinguishers? Int J Mol Sci. 2021;22(14):7622. https:\/\/doi.org\/10.3390\/ijms22147622.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1297_CR6","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","volume":"60","author":"AJ Peckett","year":"2011","unstructured":"Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60(11):1500\u201310. https:\/\/doi.org\/10.1016\/j.metabol.2011.06.012.","journal-title":"Metabolism"},{"key":"1297_CR7","doi-asserted-by":"publisher","unstructured":"Lilley JS, Linton MF, Fazio S. Oral retinoids and plasma lipids. Dermatol Ther 26(5):404\u201310. https:\/\/doi.org\/10.1111\/dth.12085","DOI":"10.1111\/dth.12085"},{"issue":"3","key":"1297_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1590\/s0365-05962012000300005","volume":"87","author":"AS Vieira","year":"2012","unstructured":"Vieira AS, Beijamini V, Melchiors AC. The effect of isotretinoin on triglycerides and liver aminotransferases. Bras Dermatol. 2012;87(3):382\u20137. https:\/\/doi.org\/10.1590\/s0365-05962012000300005.","journal-title":"Bras Dermatol"},{"issue":"8","key":"1297_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/archderm.142.8.1016","volume":"142","author":"LT Zane","year":"2006","unstructured":"Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 2006;142(8):1016\u201322. https:\/\/doi.org\/10.1001\/archderm.142.8.1016.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1297_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.metabol.2003.07.006","volume":"53","author":"D Stoll","year":"2004","unstructured":"Stoll D, Binnert C, Mooser V, Tappy L. Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in healthy humans. Metabolism. 2004;53(1):4\u201310.","journal-title":"Metabolism"},{"issue":"5","key":"1297_CR11","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1067\/mjd.2001.113719","volume":"45","author":"J McLane","year":"2001","unstructured":"McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001;45(5):S188\u201394. https:\/\/doi.org\/10.1067\/mjd.2001.113719.","journal-title":"J Am Acad Dermatol"},{"key":"1297_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1874192401105010085","volume":"5","author":"K Tziomalos","year":"2011","unstructured":"Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. Open Cardiovasc Med J. 2011;5:85\u20139. https:\/\/doi.org\/10.2174\/1874192401105010085.","journal-title":"Open Cardiovasc Med J"},{"issue":"6","key":"1297_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2165\/00002018-200124060-00003","volume":"24","author":"AK Mantel-Teeuwisse","year":"2001","unstructured":"Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf. 2001;24(6):443\u201345. https:\/\/doi.org\/10.2165\/00002018-200124060-00003.","journal-title":"Drug Saf"},{"issue":"3","key":"1297_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1185\/03007990903533681","volume":"26","author":"VA Fonseca","year":"2010","unstructured":"Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26(3):615\u201329. https:\/\/doi.org\/10.1185\/03007990903533681.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1297_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1463-1326.2008.00927.x","volume":"11","author":"DS Bell","year":"2009","unstructured":"Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and Metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009;11(3):234\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1297_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.contraception.2004.08.002","volume":"71","author":"CA Guazzelli","year":"2005","unstructured":"Guazzelli CA, Lindsey PC, de Ara\u00fajo FF, Barbieri M, Petta CA, Aldrighi JM. Evaluation of lipid profile in adolescents during long-term use of combined oral hormonal contraceptives. Contraception. 2005;71(2):118\u201321. https:\/\/doi.org\/10.1016\/j.contraception.2004.08.002.","journal-title":"Contraception"},{"issue":"3","key":"1297_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40618-015-0346-z","volume":"39","author":"M Farahmand","year":"2016","unstructured":"Farahmand M, Ramezani Tehrani F, Rostami Dovom M, Hashemi S, Azizi F. The impact of oral contraceptives on cardiometabolic parameters. J Endocrinol Invest. 2016;39(3):277\u201383. https:\/\/doi.org\/10.1007\/s40618-015-0346-z.","journal-title":"J Endocrinol Invest"},{"issue":"4 Pt 2","key":"1297_CR18","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/s0002-9378(12)90408-1","volume":"167","author":"RM Krauss","year":"1992","unstructured":"Krauss RM, Burkman RT Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynecol. 1992;167(4 Pt 2):1177\u201384. https:\/\/doi.org\/10.1016\/s0002-9378(12)90408-1.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1297_CR19","first-page":"179","volume":"48","author":"GW Creasy","year":"2003","unstructured":"Creasy GW, Fisher AC, Hall N, Shangold GA. Transdermal contraceptive patch delivering Norelgestromin and Ethinyl estradiol. Effects on the lipid profile. J Reprod Med. 2003;48(3):179\u201386.","journal-title":"J Reprod Med"},{"key":"1297_CR20","doi-asserted-by":"publisher","first-page":"892335","DOI":"10.3389\/fcvm.2022.892335","volume":"9","author":"M de Jesus","year":"2022","unstructured":"de Jesus M, Mohammed T, Singh M, Tiu JG, Kim AS. Etiology and management of dyslipidemia in patients with cancer. Front Cardiovasc Med. 2022;9:892335. https:\/\/doi.org\/10.3389\/fcvm.2022.892335.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"1297_CR21","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","volume":"8","author":"BL Kasiske","year":"2008","unstructured":"Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, Wilkinson A. Mammalian target of Rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transpl. 2008;8(7):1384\u201392. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02272.x.","journal-title":"Am J Transpl"},{"issue":"6","key":"1297_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1086\/381783","volume":"189","author":"E Fontas","year":"2004","unstructured":"Fontas E, van Leth F, Sabin CA, Friis-M\u00f8ller N, Rickenbach M, d\u2019Arminio Monforte A, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189(6):1056\u201374. https:\/\/doi.org\/10.1086\/381783.","journal-title":"J Infect Dis"},{"key":"1297_CR23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/QAI.0b013e3181648e16","volume":"47","author":"K Tassiopoulos","year":"2008","unstructured":"Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr. 2008;47:607\u201314.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1297_CR24","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1542\/peds.110.5.e56","volume":"110","author":"E Lainka","year":"2002","unstructured":"Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics. 2002;110:e56.","journal-title":"Pediatrics"},{"issue":"1","key":"1297_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1472-8206.2004.00298.x","volume":"19","author":"I Thiblin","year":"2005","unstructured":"Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam Clin Pharmacol. 2005;19(1):27\u201344. https:\/\/doi.org\/10.1111\/j.1472-8206.2004.00298.x.","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"1297_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14779072.2022.2077193","volume":"20","author":"A Joury","year":"2022","unstructured":"Joury A, Alshehri M, Li LZ, Rezan T. Androgenic steroids dysregulation and the risk of coronary artery disease. Expert Rev Cardiovasc Ther. 2022;20(5):343\u20139. https:\/\/doi.org\/10.1080\/14779072.2022.2077193.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"1297_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40261-019-00751-2","volume":"39","author":"K Buhagiar","year":"2019","unstructured":"Buhagiar K, Jabbar F. Association of first- vs. second-generation antipsychotics with lipid abnormalities in individuals with severe mental illness: a systematic review and meta-analysis. Clin Drug Investig. 2019;39(3):253\u201373. https:\/\/doi.org\/10.1007\/s40261-019-00751-2.","journal-title":"Clin Drug Investig"},{"key":"1297_CR28","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med"},{"issue":"9","key":"1297_CR29","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2174\/1570159X17666190228113348","volume":"17","author":"DD Kim","year":"2019","unstructured":"Kim DD, Barr AM, Fredrikson DH, Honer WG, Procyshyn RM. Association between serum lipids and antipsychotic response in schizophrenia. Curr Neuropharmacol. 2019;17(9):852\u201360. https:\/\/doi.org\/10.2174\/1570159X17666190228113348.","journal-title":"Curr Neuropharmacol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01297-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01297-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01297-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:23:33Z","timestamp":1745223813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01297-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01297-9","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"27 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"52"}}